Literature DB >> 23287804

Role of thiopurine metabolite testing and thiopurine methyltransferase determination in pediatric IBD.

Keith Benkov1, Ying Lu, Ashish Patel, Riad Rahhal, Gary Russell, Jonathan Teitelbaum.   

Abstract

Thiopurines have been used in inflammatory bowel disease (IBD) for >30 years, and measurements of both thiopurine methyltransferase (TPMT) and thiopurine (TP) metabolites, 6-thioguanine nucleotides (6-TGN) and 6-methylmercaptopurine (6-MMP), have been readily available. The North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) Committee on Inflammatory Bowel Disease thought it appropriate to review the present indications for use of TPMT and TP metabolite testing. Substantial evidence demonstrates that TP therapy is useful for both Crohn disease and ulcerative colitis. Review of the existing data yielded the following recommendations. TPMT testing is recommended before initiation of TPs to identify individuals who are homozygote recessive or have extremely low TPMT activity, with the latter having more reliability than the former. Individuals who are homozygous recessive or have extremely low TPMT activity should avoid the use of TPs because of concerns for significant leukopenia. TMPT testing does not predict all cases of leukopenia and has no value to predict hypersensitivity adverse effects such as pancreatitis. Any potential value to reduce the risk of malignancy has not been studied. All individuals taking TPs should have routine monitoring with complete blood cell count and white blood cell count differential to evaluate for leukopenia regardless of TPMT testing results. Metabolite testing can be used to determine adherence with TP therapy. Metabolite testing can be used to guide dose increases or modifications in patients with active disease. Consideration would include either increasing the dose, changing therapy or for those with elevated transaminases or an elevated 6-MMP, using adjunctive allopurinol to help raise 6-thioguanine metabolites and suppress formation of 6-MMP. Routine and repetitive metabolite testing has little or no role in patients who are doing well and taking an acceptable dose of a TP.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23287804     DOI: 10.1097/MPG.0b013e3182844705

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  13 in total

1.  Association between CYP2C19 extensive metabolizer phenotype and childhood anti-reflux surgery following failed proton pump inhibitor medication treatment.

Authors:  James P Franciosi; Edward B Mougey; Andre Williams; Roberto A Gomez Suarez; Cameron Thomas; Christa L Creech; Katherine George; Diana Corao; John J Lima
Journal:  Eur J Pediatr       Date:  2017-12-06       Impact factor: 3.183

Review 2.  Inflammatory Bowel Disease in Childhood and Adolescence.

Authors:  Jan Däbritz; Patrick Gerner; Axel Enninger; Martin Claßen; Michael Radke
Journal:  Dtsch Arztebl Int       Date:  2017-05-12       Impact factor: 5.594

3.  Clinical utility of thiopurine metabolite monitoring in inflammatory bowel disease and its impact on healthcare utilization in Singapore.

Authors:  Jia Qi Yeo; Hua Heng McVin Cheen; Amanda Wong; Teong Guan Lim; Balram Chowbay; Wai Fook Leong; Chunyan Wang; Ennaliza Salazar; Webber Pak Wo Chan; San Choon Kong; Wan Chee Ong
Journal:  JGH Open       Date:  2022-08-01

Review 4.  Diagnosis and management of inflammatory bowel disease in children.

Authors:  Stephanie B Oliveira; Iona M Monteiro
Journal:  BMJ       Date:  2017-05-31

5.  Predictors of azathioprine toxicity in children with autoimmune hepatitis.

Authors:  Behairy El-Sayed Behairy; Hala Hany El-Said; Hatem Abd-Alsattar Konswa; Ahmed El-Sayed Nour El-Deen; Nermin Mohamed Adawy; Ahmad Mohamed Sira
Journal:  Clin Exp Hepatol       Date:  2021-03-25

6.  Monitoring thiopurine metabolites in korean pediatric patients with inflammatory bowel disease.

Authors:  Mi Jin Kim; Soo Youn Lee; Yon Ho Choe
Journal:  Yonsei Med J       Date:  2014-09       Impact factor: 2.759

7.  Genes implicated in thiopurine-induced toxicity: Comparing TPMT enzyme activity with clinical phenotype and exome data in a paediatric IBD cohort.

Authors:  Tracy Coelho; Gaia Andreoletti; James J Ashton; Akshay Batra; Nadeem Ahmad Afzal; Yifang Gao; Anthony P Williams; Robert M Beattie; Sarah Ennis
Journal:  Sci Rep       Date:  2016-10-05       Impact factor: 4.379

8.  Clinical Pharmacogenetic Testing and Application: Laboratory Medicine Clinical Practice Guidelines.

Authors:  Sollip Kim; Yeo Min Yun; Hyo Jin Chae; Hyun Jung Cho; Misuk Ji; In Suk Kim; Kyung A Wee; Woochang Lee; Sang Hoon Song; Hye In Woo; Soo Youn Lee; Sail Chun
Journal:  Ann Lab Med       Date:  2017-03       Impact factor: 3.464

Review 9.  Thiopurine S-Methyltransferase as a Pharmacogenetic Biomarker: Significance of Testing and Review of Major Methods.

Authors:  Chingiz Asadov; Gunay Aliyeva; Kamala Mustafayeva
Journal:  Cardiovasc Hematol Agents Med Chem       Date:  2017-11-08

10.  Weekly Azathioprine Pulse versus Betamethasone Oral Mini-Pulse in the Treatment of Moderate-to-Severe Alopecia Areata.

Authors:  Prashant Gupta; Kaushal K Verma; Sujay Khandpur; Neetu Bhari
Journal:  Indian J Dermatol       Date:  2019 Jul-Aug       Impact factor: 1.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.